Menthol oil

Menthol Oil: A Comprehensive Encyclopedic Reference

1. Identity: Botanical Name, Chemical Nature, and Natural Sources

Menthol is a monoterpenoid organic compound that occurs naturally in the oils of certain plants in the mint family, such as corn mint and peppermint. It is a white or clear waxy crystalline substance that is solid at room temperature and melts slightly above. The main form of menthol occurring in nature is (−)-menthol, which is assigned the (1R,2S,5R) configuration.

Menthol (also known as mint camphor) is a cyclic monoterpene alcohol which is found as a major constituent in the essential oils of Mentha canadensis L. (cornmint) and M. x piperita L. (peppermint). The genus Mentha belongs to the Lamiaceae family and includes 42 species, 15 hybrids, and hundreds of subspecies, varieties, and cultivars. There are two well-known, so-called menthol mints in cultivation: Mentha x piperita L. (Hudson): peppermint, and Mentha arvensis L. (syn. M. canadensis L., Japanese mint): cornmint.

Peppermint originates from the Mediterranean region and is a natural hybrid between M. viridis (M. longifolia x M. rotundifolia) and M. aquatica. Mint oil from Japanese Mint (Mentha arvensis var. piperascense) contains a high (75–80%) menthol content. One of the most promising candidates for commercial extraction is Mentha arvensis, which gives its leaves a very high concentration of menthol. Menthol is present in peppermint oil as well, but the menthol yields are considered low compared to cornmint; therefore, cornmint is accepted as the best option for large-scale production.

When referring to menthol in general, it means that the l- or (−)-menthol is usually implied. Commercially, this compound is the most important natural isolate. Although menthol exists in eight stereoisomeric forms, (−)-menthol from the natural source and synthesised menthol with the same structure is the most preferred isomer.

Chemical Composition of Peppermint Essential Oil

The chemical composition of the essential oil from peppermint (Mentha x piperita L.) reveals that the main constituents are menthol (40.7%) and menthone (23.4%). Further components include (+/−)-menthyl acetate, 1,8-cineole, limonene, beta-pinene, and beta-caryophyllene. Menthol, along with menthone, isomenthone, and other compounds, imparts the cooling minty taste and smell to plants, especially to members of the Mentha genus.

Production and Extraction

Natural menthol is directly derived from mint plants following steam distillation and crystallization. It can also be produced synthetically by hydrogenation of thymol. The demand for menthol is high; worldwide use of menthol was previously estimated at 30–32,000 metric tonnes per annum. Owing to seasonal variations and poor farming practices, the availability of natural menthol from the largest supplying countries, India and China, is sometimes erratic. Only a limited amount of peppermint can be planted, thus limiting the supply of natural menthol. The remainder of the demand for menthol is met by synthetic menthol.

2. Traditional and Historical Use

Peppermint is one of the oldest known herbal remedies. Dried peppermint leaves have been found in Egyptian pyramids dating to at least 1000 BCE, and its use among the Greeks and Romans in cooking and medical preparations is well known. Hippocrates (c. 460 BC – 370 BC) considered mint as a cooling agent for peripheral pain: in early Greek times, pharmacy was related to herbal products, and the ancient Greeks had acknowledged the importance of pain therapy and had invented remedies, including those based on mint.

Originally plants were the only source of menthol and have been cultivated for medicinal purposes in Japan for ages before the compound was isolated and characterised. There are claims that this plant extract was being cultivated in Japan over 2000 years ago for medicinal use.

Peppermint was not introduced to western Europe until the eighteenth century, when it was used to treat a variety of ailments ranging from toothaches to morning sickness. It was first brought to the United States about a century later. In 1721, peppermint first appeared in the London Pharmacopoeia, with the first isolation of the menthol compound by the Dutch botanist Gambius in 1771.

Mint herbs have been used since ancient times for various purposes such as the management of vomiting, reduction of gas in the stomach, facilitation of digestion, management of cough, oral hygiene, heart health, skin health, and pain relief. Mint has been suggested in traditional Persian medicine for the treatment of oligomenorrhea and amenorrhea. Peppermint and spearmint fragrances were used in embalming and perfumes.

From the earliest scripts in ancient Egypt detailing medical practices through to ancient Greece and the earliest description of the cooling analgesic benefits of mint by Hippocrates, it is evident that throughout history the Mentha herb has been popularly used by various peoples and civilizations for a wide range of uses including pain relief. Traditional preparations included infusions, poultices, and topical applications of expressed leaf oils.

3. Key Constituents and Active Compounds

While the term "menthol oil" is used colloquially, the product traded and researched may refer either to isolated menthol (the pure crystalline compound) or to peppermint essential oil (in which menthol is the dominant active constituent). The primary bioactive constituents are:

• L-Menthol ((−)-menthol): The main form of menthol occurring in nature is (−)-menthol, which is assigned the (1R,2S,5R) configuration. It is responsible for the characteristic cooling sensation and the majority of pharmacological activity.
• Menthone: A ketone co-occurring with menthol and contributing to the oil's characteristic aroma and, along with menthol, its biological activity.
• Menthyl acetate: Menthyl acetate is a further component of peppermint essential oil alongside 1,8-cineole, limonene, beta-pinene, and beta-caryophyllene.

Menthol is one of the most effective terpenes used to enhance the dermal penetration of pharmaceuticals.

4. Mechanisms of Action

TRPM8 (Cold Receptor) Activation

The transient receptor potential melastatin 8 (TRPM8) ion channel is the primary cold sensor in humans. TRPM8 is gated by physiologically relevant cold temperatures and chemical ligands that induce cold sensations, such as the analgesic compound menthol. Menthol acts upon TRPM8 receptors by rapidly increasing intracellular calcium and mobilizing calcium flux through the channels to induce cold response signals at the application site.

Under physiological conditions, low to moderate concentrations of menthol activate TRPM8 in primary nociceptors, such as dorsal root ganglion (DRG) and trigeminal ganglion, generating a cooling sensation, whereas menthol at higher concentration could induce cold allodynia, and cold hyperalgesia mediated by TRPM8 sensitization. The paradoxical irritating properties of high concentrations of menthol are associated with its activation of transient receptor potential cation channel subfamily A member 1 (TRPA1).

Multi-Target Analgesic Mechanisms

The analgesic mechanisms of menthol and its derivatives involve multi-target modulation, including TRP channel activation, opioid receptor agonism, GABAergic system potentiation, and ion channel blockade, which synergistically suppress nociceptive signaling at both peripheral and central levels.

Researchers conducting hotplate and abdominal constriction tests on mice found that (−)-menthol produced analgesia by activating κ-opioid receptors (KOR), and this effect could be blocked by opioid receptor antagonists. Menthol activates γ-aminobutyric acid type A (GABA_A) receptors by binding to the β-subunit, enhancing chloride ion influx and hyperpolarizing neurons, thereby reducing nociceptive transmission. Concurrently, menthol blocks voltage-gated Na⁺ and Ca²⁺ channels in a use-dependent manner, suppressing repetitive firing and action potential amplitude in nociceptors. This dual action—GABA_A activation and ion channel blockade—synergistically decreases neuronal excitability in the spinal cord, contributing to its central analgesic effects.

Gastrointestinal Smooth Muscle Relaxation

Peppermint oil contains L-menthol, which blocks calcium channels in smooth muscle, thus producing antispasmodic effects on the gastrointestinal tract. Menthol reduces intestinal muscle spasms by reducing the influx of calcium ions in the nerve cells that activate muscle contraction and inhibiting their action potential.

Topical Counterirritant and Penetration Enhancement

Menthol is a selective activator of TRPM8 channels and is also a vasoactive compound. As a topical agent, it acts as a counter-irritant by imparting a cooling effect and by initially stimulating nociceptors and then desensitizing them. Topically applied menthol may also activate central analgesic pathways. When applied to the skin, it initially stimulates the nerve endings, but continued exposure desensitizes the nerve endings and decreases pain sensitivity.

Anti-inflammatory Effects

The decrease in pro-inflammatory cytokines and related inflammatory markers, as well as associated pathway activation, was found to play the greatest role in the protective effects of menthol against inflammatory damage or association with protection against chronic inflammation. Further studies are needed to establish relationships between the mechanisms of action and to clarify the clinical relevance of any anti-inflammatory effects.

5. Scientific Evidence by Area of Use

5.1 Irritable Bowel Syndrome (IBS)

The gastrointestinal use of peppermint oil (via its menthol content) has the strongest and most consistent clinical evidence base of any application for this ingredient.

Twelve randomized trials with 835 patients were included in a major meta-analysis examining peppermint oil for IBS. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of peppermint oil (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% confidence interval (CI): 1.93, 2.97], I² = 0%, z = 7.93 (p < 0.00001).

A 4-week, randomized, double-blind, placebo-controlled clinical trial examined peppermint oil or identical placebo administered 3 times daily in patients fulfilling Rome III criteria for IBS-M or IBS-D, with the primary endpoint being change from baseline in the Total IBS Symptom Score (TISS). Seventy-two patients (mean age 40.7 years, 75% female, 77.8% white) were randomized to peppermint oil (n = 35) or placebo (n = 37). At 4 weeks, peppermint oil was associated with a 40% reduction in the TISS from baseline, superior to the 24.3% decrease observed with placebo (P = 0.0246).

A small amount of research suggests that peppermint oil in enteric-coated capsules may improve IBS symptoms in adults. A 2022 review of 10 studies (involving 1,030 participants) found that peppermint oil was better than placebo at improving overall IBS symptoms and reducing abdominal pain, but caused more side effects than placebo. Most of the side effects were mild and included acid reflux and indigestion. A 2021 clinical guideline from the American College of Gastroenterology recommended the use of peppermint oil for relief of overall IBS symptoms and noted that enteric-coated formulations might help with acid reflux and indigestion side effects.

European, Canadian, and Japanese clinical practice guidelines recommend peppermint oil to alleviate IBS symptoms. One systematic review concluded that peppermint oil is a safe and effective short-term treatment for IBS, while noting that future studies should assess the long-term efficacy and safety of peppermint oil and its efficacy relative to other IBS treatments including antidepressants and antispasmodic drugs.

Evidence strength: Moderate-to-strong for short-term IBS symptom relief in adults. Multiple RCTs and several meta-analyses with consistent directional findings, guideline endorsement. Long-term safety data are limited.

5.2 Topical Analgesia (Musculoskeletal and Neuropathic Pain)

Menthol, the cooling natural product of peppermint, is widely used in medicinal preparations for the relief of acute and inflammatory pain in sports injuries, arthritis and other painful conditions. Menthol induces the sensation of cooling by activating TRPM8, an ion channel in cold-sensitive peripheral sensory neurons. Recent studies have identified additional targets of menthol, including the irritant receptor TRPA1, voltage-gated ion channels, and neurotransmitter receptors.

Using genetic and pharmacological approaches in mice, L-menthol effectively diminished pain behavior elicited by chemical stimuli (capsaicin, acrolein, acetic acid), noxious heat and inflammation (complete Freund's adjuvant). The data from that study show that TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Most human clinical data in topical analgesia use menthol-containing proprietary preparations rather than isolated menthol, limiting precise dose-response conclusions in humans.

Evidence strength: Moderate mechanistic evidence from preclinical models; human clinical trial data on isolated menthol topical analgesia is more limited and often confounded by combination products.

5.3 Headache (Tension-Type and Migraine)

Topical application of peppermint oil may be effective in the treatment of tension headache. Topical application of 10% menthol produced a significant effect on pain, outperforming placebo and also improving associated symptoms such as nausea and sensitivity to light and sound.

Preliminary research also shows that intranasal peppermint oil at 1.5% may be as effective as intranasal lidocaine 4% in reducing migraine intensity, with effects felt in as little as 5 minutes for some patients. TRPM8 may be expressed in the sensory afferents associated with the meninges, which may contribute to migraine. In humans, it has been observed that cold can trigger a migraine but, alternately, the cooling action of menthol can alleviate headache pain. Thus, TRPM8 may be considered a potential target for personalized medicine or migraine therapy, and the role of menthol may be important.

Evidence strength: Preliminary to moderate. A small number of controlled studies support the use of topical 10% peppermint oil for tension-type headache. Migraine data are very early stage. Larger, well-powered RCTs are needed.

5.4 Nasal Congestion and Respiratory Symptoms

Menthol has been demonstrated to cause a subjective nasal decongestant effect without any objective decongestant action, and administration of menthol via a nasal inhaler in humans has also been shown to cause nasal decongestion.

Clinical trials assessing the efficacy of an ointment containing menthol, eucalyptus, and camphor found patients to experience faster nasal cooling and decongestion times. Treatment with the same ointment also resulted in significant improvements in reported sleep quality.

The effect of inhaled menthol vapor on asthma was studied in a placebo-controlled trial of 23 patients. The menthol vapor did not produce immediate bronchodilatory effects, but inhalation over 4 weeks resulted in a decreased diurnal variation in peak expiratory flow rate (p < 0.05), a value which signifies a reduction in airway hyperresponsiveness. The number of metered dose inhaler inhalations were also significantly reduced in the menthol group (p < 0.01).

Eucalyptol, menthol, and gingerol exhibited significant anti-inflammatory and mucolytic effects, supporting nasal and bronchial decongestion.

Evidence strength: The subjective decongestant and comfort benefit for upper respiratory symptoms is supported by controlled trials, but objective nasal patency measurements do not always confirm decongestant action. Data on respiratory use in asthma are very preliminary (small single trial). Menthol's nasal effects appear largely sensory (TRPM8-mediated cooling perception) rather than structural.

5.5 Gastrointestinal Antispasmodic Uses Beyond IBS

A small amount of research suggests that peppermint oil might be helpful to reduce spasms during certain procedures, such as endoscopy or barium enema examination. Because of its relaxing effects on smooth muscle, peppermint oil given via enema has been modestly effective for relief of colonic spasm in patients undergoing barium enemas.

In a double-blind, placebo-controlled multi-center trial, 54 patients with non-ulcer dyspepsia were given one enteric-coated capsule per day containing 90 mg peppermint oil and 50 mg of caraway oil. After 4 weeks, intensity of pain was significantly decreased and global clinical impressions improved.

A combination product including peppermint oil and caraway oil seems to be moderately effective in the treatment of non-ulcer dyspepsia. Quality clinical trials are lacking to recommend use for treatment of dyspepsia as a standalone therapy.

Evidence strength: Moderate for procedure-related GI antispasmodic use (endoscopy). Preliminary but encouraging for functional dyspepsia, primarily in combination preparations.

5.6 Anticancer Activity

Anticancer research on menthol is an active and expanding field, but almost entirely preclinical (in vitro and animal models) at this time.

Menthol, a widely used natural, active compound, has recently been shown to have anticancer activity, and it has been found to have a promising future in the treatment of various solid tumors.

In previous studies, menthol has been reported as an anti-cancer agent in several cancer types via the TRPM8-dependent pathway or in a TRPM8-independent manner. Cell death induction in human bladder cancer T24 cells has been associated with TRPM8, which occurs via menthol increasing the concentration of intracellular calcium and inducing mitochondrial membrane depolarization through TRPM8 channels. In addition, menthol has exerted anti-tumor activity in prostate cancer DU145 cells via upregulating TRPM8 expression, leading to anti-proliferation and inhibition of motility.

In studies using Caco-2 cells (colon cancer), L-menthol was found to downregulate heat shock protein 90, additionally activated caspase3 and caspase10. These alterations further inhibit AKT-related pathways to induce the release of the pro-apoptotic factor BAD from the BAD and BCL2L1 complexes.

Nagai et al. reported that menthol enhances the effect of anti-cancer drugs Paclitaxel and Vincristine on human hepatocellular carcinoma HepG2 cells, where cell viability was significantly decreased through downregulation of CYP3A4.

Evidence strength: Clinical trials validating the systemic effects of menthol in humans—particularly in the domains of oncology, aging, and neurodegeneration—are still limited. Owing to the excellent anticancer activity menthol has demonstrated in preclinical settings, further research is warranted for developing it as a novel anticancer agent. However, there are limitations and gaps in the current research on menthol, and its antitumor mechanism has not been completely elucidated. All current anticancer evidence must be characterized as preliminary and preclinical.

5.7 Antimicrobial Activity

Plants containing menthol are known to exhibit biological activity in vitro and in vivo such as antibacterial, antifungal, antipruritic, anticancer, and analgesic effects, and are also an effective fumigant. Menthol, a natural compound in peppermint leaves, has several biological activities, including antioxidant, anti-inflammatory, antiviral, antibacterial, and anticancer properties.

Evidence strength: Antimicrobial activity is primarily established in in vitro (cell culture) models. Clinical translation into human antimicrobial therapeutic applications has not been adequately studied in registered clinical trials.

6. Body Systems and Health Areas Associated with Menthol

This compound demonstrates multifaceted therapeutic potential, spanning anti-inflammatory, immunomodulatory, antioxidant, antimicrobial, antiviral, analgesic, antispasmodic, anti-aging, anticancer, and wound-healing activities. The primary body systems implicated by existing evidence include:

• Nervous system (peripheral): TRPM8-mediated cold sensation, pain modulation, and kappa-opioid receptor activation.
• Gastrointestinal system: Calcium channel blockade in smooth muscle producing antispasmodic effects, supporting IBS and dyspepsia applications.
• Respiratory system: Subjective nasal decongestant effects via TRPM8 stimulation; potential mucolytic and anti-inflammatory effects in the upper airway.
• Musculoskeletal system: Menthol, the cooling natural product of peppermint, is widely used in preparations for pain relief in sports injuries, arthritis, and other painful conditions.
• Skin (dermal): Penetration enhancement, antipruritic (anti-itch), and topical analgesic action. Menthol is used as an antipruritic to reduce itching, and as a topical analgesic to relieve minor aches and pains, such as muscle cramps, sprains, headaches, and similar conditions.
• Oncological (experimental): TRPM8 channel modulation in various cancer cell lines, apoptosis induction — currently preclinical only.

7. Dosage Forms and Dosages Reported in Studies

Typical delivery forms include enteric-coated capsules, essential oil, liquid extract or tincture, dried leaf as infusion (tea), aqueous ethanol preparations, ointments, salves, and lozenges.

Oral (Enteric-Coated Capsules) — Gastrointestinal Applications

The therapeutic dosage range studied in most IBS trials was 0.2 to 0.4 mL of peppermint oil taken three times daily in enteric-coated capsules. The dosage used in the single clinical trial in children was 0.1 mL three times daily for children weighing less than 45 kg.

Up to 1,200 mg daily (180 to 400 mg 3 times daily) of peppermint oil in enteric-coated capsules has been used to treat nonserious constipation and diarrhea associated with IBS.

In one RCT, the specifications of the peppermint oil included a high level (47.5 ± 2.5%) of free l-menthol, with 90 mg of peppermint oil and 41.5 mg of free l-menthol per capsule. A standard dose of two capsules contains approximately 83 mg of l-menthol, designed to release over 4 hours after exiting the stomach.

The trials for dyspepsia used a dose of 90 mg of peppermint oil in combination with 50 mg of caraway oil in a specific standardized preparation.

Topical — Headache and Pain

Topical application of 10% menthol produced a significant effect on pain in headache trials, outperforming placebo and improving associated symptoms such as nausea and sensitivity to light and sound.

Preliminary research shows that intranasal peppermint oil at 1.5% may be as effective as intranasal lidocaine 4% in reducing migraine intensity.

Pharmacokinetics

A pharmacokinetic study of a single immediate-release, 100-mg dose of l-menthol in healthy adults detected only menthol glucuronide in plasma or urine, while no free menthol was detected. Pharmacokinetic studies reveal that fractionated urinary recovery of menthol is dependent on the kind of formulation used. Optimal pH-triggered enteric-coated formulations start releasing peppermint oil in the small intestine, extending release over 10–12 hours, thus providing peppermint oil to the target organ in irritable bowel syndrome.

Formulation Rationale for Enteric Coating

Capsules containing peppermint oil are often enteric-coated to reduce the likelihood of heartburn. If peppermint oil is released from its dosage form prior to passing through the pyloric sphincter into the intestines, it can irritate the mucous membranes in the upper digestive tract. Releasing peppermint oil directly into the stomach can cause heartburn and gastro-esophageal reflux disease. Therefore, since peppermint oil is usually administered orally, it should preferably be prepared with an enteric coating.

8. Safety Considerations and Interactions

General Safety Profile

Peppermint oil appears to be safe when taken orally (by mouth) or applied topically in the doses commonly used. Peppermint oil has been safely used in multiple clinical trials. The United States Food and Drug Administration and the Flavoring Extract Manufacturer's Association generally consider menthol a safe substance, and its toxicities are rarely reported in the literature.

Oral Side Effects

Possible side effects of peppermint oil taken orally include heartburn, nausea, abdominal pain, and dry mouth. Rarely, peppermint oil can cause allergic reactions. Several adverse effects of peppermint oil have been reported that include dermatitis, cheilitis, mouth ulceration, abdominal pain, nausea, vomiting, bradycardia, and tremor.

Topical and Inhalation Side Effects

Side effects of applying peppermint oil to the skin can include skin rashes and irritation. Inhaling peppermint oil can result in irritation of the nose and throat, cough, and shortness of breath from the menthol. Topical menthol treatment is often accompanied by skin irritation, and inhalation of menthol can aggravate asthma in some patients, which may be the role of TRPA1.

Toxicity at High Doses

Ingestion of pure menthol can be dangerous and its overdosage is possible with excess consumption of menthol-containing products. Orally, the lethal dose has been estimated as 50–150 mg/kg. Excessive amounts of menthol have been suggested to cause vertigo, dizziness, agitation, nystagmus, ataxia, hallucinations, lethargy, and coma.

Use in Infants and Children

Peppermint oil should not be applied to the face of infants or young children because serious side effects may occur if they inhale the menthol in the oil. Peppermint oil in a gel, water, or cream applied topically to the nipple area of breastfeeding women might be helpful for reducing pain and cracked skin. Menthol should not be inhaled by or applied to the face of an infant or small child because it may negatively affect their breathing. Peppermint oil should therefore be used only after breastfeeding and then wiped off before the next breastfeeding session.

Pregnancy and Breastfeeding

Use of oral peppermint in amounts commonly found in food is likely safe during pregnancy or while breastfeeding, but little is known about whether it is safe to use oral peppermint in medicinal amounts during pregnancy or while breastfeeding.

Drug Interactions — CYP3A4 Inhibition

Co-administration of peppermint leaf essential oil (600 mg) and felodipine (a calcium antagonist drug used to control hypertension) moderately increased the plasma concentration of felodipine, possibly through inhibition of the drug-metabolizing isoenzyme CYP3A4. Peppermint oil, menthol, menthyl acetate, and ascorbyl palmitate were moderately potent reversible inhibitors of in vitro CYP3A4 activity. This interaction may be clinically significant for other drugs metabolized by CYP3A4.

GERD and Lower Esophageal Sphincter

Menthol enhances smooth muscle relaxation and reduces lower esophageal sphincter tone. This means that non-enteric-coated menthol preparations may worsen gastroesophageal reflux disease (GERD) symptoms, and peppermint oil is generally not recommended in those with GERD unless given in enteric-coated form.

Mentholated Cigarettes

Menthol's cold-sensitivity response mechanism has been shown to inhibit mucosal recognition of nicotine and cigarette toxins common in mentholated cigarette brands, thus potentially leading to toxic effects. Menthol flavoring in cigarettes might be associated with a higher rate of addiction to smoking. This is an important public health consideration distinct from therapeutic use.

Evidence Quality and Gaps

While menthol is generally well tolerated, attention to concentration, formulation, route of administration, and patient-specific factors is essential. Integrating menthol into evidence-based clinical medicine will depend on the implementation of standardized, high-quality clinical trials that determine appropriate formulations, dosing regimens, and validated outcome measures.

References

• Eccles R. Menthol: pharmacology of an important naturally medicinal "cool" compound. Current Drug Targets, 2012. PubMed PMID 23061635.
• Kamatou GPP, Vermaak I, Viljoen AM, Lawrence BM. Menthol: A simple monoterpene with remarkable biological properties. Phytochemistry, 2013.
• Kalemba D, Synowiec A. Agrobiological Interactions of Essential Oils of Two Menthol Mints: Mentha piperita and Mentha arvensis. Molecules, 2019. PMC6983130.
• Iscan G, et al. Chemical composition, olfactory evaluation and antioxidant effects of essential oil from Mentha x piperita. Journal of Agricultural and Food Chemistry, 2002. PubMed PMID 19768994.
• PMC Review: Menthol and Its Derivatives: Exploring the Medical Application Potential. PMC12425124.
• Liu B, et al. TRPM8 is the Principal Mediator of Menthol-induced Analgesia of Acute and Inflammatory Pain. Pain, 2013. PMC3778045.
• Zhou Y, et al. The distinctive role of menthol in pain and analgesia: Mechanisms, practices, and advances. Frontiers in Molecular Neuroscience, 2022. PMC9580369.
• Phelps PT, et al. Implications of human TRPM8 channel gating from menthol binding studies of the sensing domain. PMC4865251.
• Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Digestive Diseases and Sciences, 2016. PMC4729798.
• Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Journal of Clinical Gastroenterology, 2014. PubMed PMID 24100754.
• Alammar N, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complementary and Alternative Medicine, 2019. PMC6337770.
• Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome. PMC10854076.
• National Center for Complementary and Integrative Health (NCCIH). Peppermint Oil: Usefulness and Safety.
• Raman S, et al. A fatal case of menthol poisoning. PMC4830155.
• Baibars M, et al. Menthol Toxicity: An Unusual Cause of Coma. Case Reports in Medicine, 2012. PMC3521632.
• Smith A, et al. Aromatic ointments for the common cold: what does the science say? Drugs in Context, 2022. PMC9354706.
• Cheng H, An X. Cold stimuli, hot topic: An updated review on the biological activity of menthol in relation to inflammation. Frontiers in Immunology, 2022. PMC9682018.
• Zhao Y, et al. Menthol: An underestimated anticancer agent. Frontiers in Pharmacology, 2023. PMC10063798.
• Anti-leukemic effect of menthol, a peppermint compound, on induction of apoptosis and autophagy. PMC10010179.
• Pergolizzi JV Jr, et al. The role and mechanism of action of menthol in topical analgesic products. Journal of Clinical Pharmacy and Therapeutics, 2018. PMID 29524352.
• Grigoleit HG, Grigoleit P. Peppermint Oil. American Family Physician, 2007.
• Grigoleit HG, Grigoleit P. Gastrointestinal clinical pharmacology of peppermint oil. Phytomedicine, 2005. PubMed PMID 16121522.
• Baser KHC, Erdag E, Haskologlu IC. Menthol: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Applications. Natural Product Communications, 2025.
• Menthol: An exploration from antiquity to modernity. IASP World Congress 2024 Poster.
• Comparing the Effect of Intranasal Lidocaine 4% with Peppermint Essential Oil Drop 1.5% on Migraine Attacks: A Double-Blind Clinical Trial. PMC6647908.